Terumo (OTCMKTS:TRUMY) Shares Gap Down - Here's Why

Key Points

• Terumo Corp.'s shares experienced a significant gap down, opening at $16.88, compared to the previous close of $17.77.
• Despite a 1.0% decline, Terumo reported a quarterly earnings beat with an EPS of $0.20, exceeding estimates, although revenues of $1.76 billion fell short of the expected $1.80 billion.
• The company has a market capitalization of $26.06 billion and operates in various regions, producing medical products and equipment.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report)'s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $17.77, but opened at $16.88. Terumo shares last traded at $17.75, with a volume of 3,425 shares trading hands.

Terumo Trading Down 1.0%

The stock has a 50 day moving average of $17.56 and a 200-day moving average of $18.21. The company has a market capitalization of $26.06 billion, a P/E ratio of 30.88 and a beta of 0.79. The company has a current ratio of 2.64, a quick ratio of 1.53 and a debt-to-equity ratio of 0.07.

Terumo (OTCMKTS:TRUMY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.17 by $0.03. Terumo had a return on equity of 9.19% and a net margin of 12.09%.The business had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.80 billion.

Terumo Company Profile

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.